Skip to main content
SAM CHUN DANG PHARM CO. LTD logo

SAM CHUN DANG PHARM CO. LTD — Investor Relations & Filings

Ticker · 000250 ISIN · KR7000250001 KO Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2025-10-22 Capital/Financing Update
Country KR South Korea
Listing KO 000250

About SAM CHUN DANG PHARM CO. LTD

http://www.scd.co.kr/english/scd/index.…

SAM CHUN DANG PHARM CO. LTD. is a pharmaceutical company focused on the development, manufacturing, and sale of medications. The company specializes in ophthalmic products, establishing itself as a significant player in the generic eye care market. Its portfolio also extends to other therapeutic areas, including antibiotics and medications for the circulatory system. The company produces a range of ethical (prescription) and over-the-counter (OTC) drugs in both sterile and non-sterile forms. Manufacturing operations adhere to international quality standards, holding both US and EU Good Manufacturing Practice (GMP) certifications.

Recent filings

Filing Released Lang Actions
타법인주식및출자증권취득결정(자율공시)
Capital/Financing Update Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the decision to acquire shares and equity securities of another company (Optus Pharma). It includes details such as the number of shares to be acquired, acquisition amount, ownership percentage after acquisition, acquisition method, purpose, and relevant financial data of the target company. The document is an announcement of a capital investment transaction rather than a financial report or earnings release. It does not contain comprehensive financial statements or management discussion but focuses on the acquisition decision and related details. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2211 characters, which is consistent with an announcement rather than a full report.
2025-10-22 Korean
투자판단관련주요경영사항 (비젠프리(SCD411, 아일리아 바이오시밀러) VIAL 및 PFS(Pre-filled Syringe) 한국 품목허가 획득)
Regulatory Filings Classification · 75% confidence The document is a regulatory announcement on the Korea Exchange detailing a material corporate event (Korean product approval from the MFDS). It does not contain financial statements, management discussion, or voting results, nor is it an investment presentation or earnings release. It fits the fallback “Regulatory Filings” category for general announcements of material events (Code: RNS).
2025-09-22 Korean
투자판단관련주요경영사항 (황반변성치료제(아일리아/주성분 : Aflibercept) 바이오시밀러 SCD411(Vial&PFS)의 동유럽 8개국(폴란드, 체코, 슬로바키아, 헝가리, 리투아니아, 라트비아, 에스토니아, 루마니아) 독점판매권 및 공급계약 체결)
Regulatory Filings Classification · 85% confidence The document is a Korean ‘투자판단 관련 주요경영사항’ disclosure announcing a material contract (exclusive distribution/supply agreement) for a biosimilar product in eight Eastern European countries. It does not present financial statements (so not an interim or annual report), nor is it an earnings release, capital-raising update, M&A, dividend, or proxy statement. It is a general regulatory announcement of a material business event that falls into the fallback “Regulatory Filings (RNS)” category.
2025-09-22 Korean
[기재정정]주요사항보고서(교환사채권발행결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from Samchundang Pharm, specifically detailing the 'Decision to Issue Exchangeable Bonds' (교환사채권 발행결정). It includes a correction (정정신고) regarding the bond series and the specific investors involved. This type of filing relates to corporate financing and capital structure changes, which falls under the 'Capital/Financing Update' category.
2025-09-19 Korean
[기재정정]주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the 'Decision to Dispose of Treasury Shares' (자기주식 처분 결정). It details a correction (정정신고) to a previous filing concerning the disposal of treasury shares through the issuance of exchangeable bonds. Since this document reports the company's decision to sell/dispose of its own shares, it falls under the 'Transaction in Own Shares' category.
2025-09-19 Korean
자기주식처분결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '자기주식처분결과보고서' (Report on the Results of Disposal of Treasury Shares) filed with the Financial Supervisory Service (FSS) of South Korea. It details the disposal of treasury shares by Samchundang Pharm Co., Ltd. in connection with the issuance of exchangeable bonds. This document specifically reports the execution and results of a share disposal transaction, which falls under the category of 'Transaction in Own Shares' (POS).
2025-09-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.